{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:37:50Z","timestamp":1767713870982},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Aim Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.<\/jats:p><jats:p>\n          Methods I-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.<\/jats:p><jats:p>\n          Results Many studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.<\/jats:p><jats:p>\n          Conclusion This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.<\/jats:p>","DOI":"10.1055\/a-1759-2050","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T22:46:46Z","timestamp":1654296406000},"page":"231-239","source":"Crossref","is-referenced-by-count":2,"title":["I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma"],"prefix":"10.1055","volume":"61","author":[{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Kayano","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anri","family":"Inaki","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/HJH.0000000000002438","article-title":"Phaeochromocytoma","volume":"366","author":"JW Lenders","year":"2005","journal-title":"LANCET"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma","volume":"60","author":"G Eisenhofer","year":"2014","journal-title":"CLIN CHEM"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"R Garcia-Carbonero","year":"2021","journal-title":"CLIN TRANSL ONCOL"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters","volume":"89","author":"L K\u00f6lby","year":"2003","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/ijc.2910470615","article-title":"Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging","volume":"47","author":"MN Gaze","year":"1991","journal-title":"INT J CANCER"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"F Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0b013e3181feeb5e","article-title":"Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT\/CT over planar image in patients with malignant pheochromocytoma\/paraganglioma and neuroblastoma","volume":"36","author":"M Fukuoka","year":"2011","journal-title":"CLIN NUCL MED"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"D Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1210\/jc.2003-031091","article-title":"Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma","volume":"89","author":"I Ilias","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","first-page":"217","article-title":"Nuclear medicine imaging of pheochromocytoma and neuroblastoma","volume":"43","author":"JC Sisson","year":"1999","journal-title":"Q J Nucl Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1210\/jcem.86.2.7238","article-title":"(123)I]metaiodobenzylguanidine and [(111)In","volume":"86","author":"E van der Harst","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"GA Wiseman","year":"2009","journal-title":"J NUCL MED"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative \u00b9\u00b2\u00b3I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"JS Fonte","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"I Janssen","year":"2016","journal-title":"J NUCL MED"},{"issue":"S 01","key":"ref15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000173960","article-title":"131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma","volume":"72","author":"B Shapiro","year":"1985","journal-title":"CARDIOLOGY"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","article-title":"Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre","volume":"108","author":"MA Rutherford","year":"2015","journal-title":"QJM"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of \u00b9\u00b3\u00b9I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"K Yoshinaga","year":"2014","journal-title":"ENDOCR J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","article-title":"Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma","volume":"27","author":"H Wakabayashi","year":"2013","journal-title":"ANN NUCL MED"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.1038\/s41598-019-43880-6","article-title":"A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma","volume":"9","author":"H Wakabayashi","year":"2019","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience","volume":"33","author":"M Shilkrut","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"ref21","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"B Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"ref22","first-page":"100","article-title":"(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"MR Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/s0039-6060(03)00426-4","article-title":"Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"SD Safford","year":"2003","journal-title":"SURGERY"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"GK Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref25","doi-asserted-by":"publisher","first-page":"dgz074","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"MP Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1196\/annals.1353.050","article-title":"Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"1073","author":"PA Fitzgerald","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"ref27","first-page":"239","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"B Rose","year":"2003","journal-title":"CANCER-AM CANCER SOC"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"S Gonias","year":"2009","journal-title":"J CLIN ONCOL"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"KC Loh","year":"1997","journal-title":"J ENDOCRINOL INVEST"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/01.mnm.0000184941.06123.b9","article-title":"Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response","volume":"26","author":"JR Buscombe","year":"2005","journal-title":"NUCL MED COMMUN"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"LT van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/clon.2001.9290","article-title":"Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands","volume":"13","author":"A Hartley","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/00000421-199908000-00008","article-title":"Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy","volume":"22","author":"JC Sisson","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/RLU.0000000000000973","article-title":"Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation","volume":"41","author":"W Makis","year":"2016","journal-title":"CLIN NUCL MED"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fonc.2014.00166","article-title":"External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma","volume":"4","author":"J Vogel","year":"2014","journal-title":"FRONT ONCOL"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0032-1308992","article-title":"External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG","volume":"44","author":"L Fishbein","year":"2012","journal-title":"HORM METAB RES"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-j","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"AT Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0032-1311603","article-title":"Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy","volume":"44","author":"J Spetz","year":"2012","journal-title":"HORM METAB RES"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1196\/annals.1353.052","article-title":"Aspects on radionuclide therapy in malignant pheochromocytomas","volume":"1073","author":"E Forssell-Aronsson","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy","volume":"61","author":"TA Hope","year":"2020","journal-title":"J NUCL MED"},{"key":"ref41","first-page":"288","article-title":"[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma","volume":"35","author":"J Lumbroso","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with (131)I-MIBG therapy","volume":"109","author":"WC Sze","year":"2013","journal-title":"Br J Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13139-018-0523-z","article-title":"Current Consensus on I-131 MIBG Therapy","volume":"52","author":"D Kayano","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma","volume":"46","author":"JA Carrasquillo","year":"2016","journal-title":"SEMIN NUCL MED"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"JJ Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"DA Pryma","year":"2019","journal-title":"J NUCL MED"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"RB Noto","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/cbr.2008.0584","article-title":"Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"RE Coleman","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2967\/jnumed.109.064469","article-title":"Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma","volume":"50","author":"SE Buckley","year":"2009","journal-title":"J NUCL MED"},{"key":"ref50","first-page":"1713","article-title":"Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG","volume":"42","author":"KK Matthay","year":"2001","journal-title":"J NUCL MED"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/cbr.2005.20.195","article-title":"Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma","volume":"20","author":"MN Gaze","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/108497803321269359","article-title":"Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG","volume":"18","author":"GD Flux","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40658-020-0282-7","article-title":"EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours","volume":"7","author":"J Gear","year":"2020","journal-title":"EJNMMI Phys"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1759-2050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T22:47:06Z","timestamp":1654296426000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1759-2050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":53,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,6,3]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1759-2050","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}